Roche has agreed to pay Nurix Therapeutics $700 million upfront and commit to up to $2.3 billion in milestones to co-develop and co-commercialize bexobrutideg, an oral BTK degrader for B-cell malignancies. The collaboration sets up a competitive head-to-head against Eli Lilly’s Jaypirca in a planned Phase 3 confirmatory trial. Roche and Nurix said the strategy is built around degrading BTK rather than inhibiting its enzymatic activity, aiming to eliminate not only kinase signaling but also BTK scaffolding functions. Roche will fund 60% of development costs, split U.S. profits through a co-promotion model, and handle commercialization outside the U.S. with royalties in the low- to high-teens. Nurix reported median progression-free survival of 22.1 months in a Phase 1a setting, compared with 14 months in Lilly’s Phase 3 program for Jaypirca, though cross-trial comparisons carry obvious limitations. Nurix said the company dosed the first patient in a potentially pivotal Phase 2 trial in October, including patients previously treated with covalent and non-covalent BTK inhibitors. The deal underscores how quickly the BTK franchise is shifting toward next-generation modalities, with protein degraders emerging as a differentiated mechanism as regulators and payers weigh additional options for patients progressing on current standards of care.